Bengaluru: Serum Institute of India (SII), the world’s largest vaccine producer by volume, is close to signing a supply contract with the Central government and is likely to fix prices at ₹ 250 per dose of the covid-vaccine.
The government is clasping its hopes for the bulk supply of covid-vaccine by the Serum Institute of India (SII), which had lodged the first formal appeal for the emergency-use consent for the AstraZeneca’s shot on Monday.
Chief Executive Officer of SII had earlier said the vaccine would be priced at 1,000 rupees ($13.55) per dose in India’s private medical market, but the governments signing a large supply deal, would likely make it available to the public at lower prices.
The SII will first focus on satisfying the vaccine needs of the Indians before distributing it to other countries.
Serum Institute of India’s Tweet Regarding the Made in India Covid-Vaccine:
IMPORTANT UPDATE https://t.co/M8LNzmJ6Xl— SerumInstituteIndia (@SerumInstIndia) December 7, 2020
With 9.70 million COVID-19 cases recorded so far, India is second immediately after the United States and is hastening its review of Covid-vaccines developed by Pfizer Inc and AstraZeneca to approve for emergency use.